Back to School: How biopharma can reboot drug development. Access exclusive analysis here

OncoMed, GlaxoSmithKline deal

OncoMed will use its xenograft cancer models to identify MAbs against cancer

Read the full 121 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE